The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.125
Bid: 0.05
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.15 (300.00%)
Open: 0.125
High: 0.125
Low: 0.125
Prev. Close: 0.125
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

8 Sep 2022 07:00

RNS Number : 6791Y
Byotrol PLC
08 September 2022
 

 

08/09/2022

Byotrol plc

("Byotrol" or the "Company")

 

Director Dealing

 

Byotrol plc (AIM: BYOT), the developer of anti-microbial hygiene technologies, announces that on 7 September 2022, Chris Sedwell, Chief Financial Officer of the Company, purchased 188,436 ordinary shares of 0.25p each ("Ordinary Shares") at an average price of 2.63p per Ordinary Share (the "Purchase").

 

Following the Purchase, Chris Sedwell has an interest in 188,436 Ordinary Shares representing 0.04% of the total voting rights of the Company.

 

 

Byotrol Plc

David Traynor - Chief Executive Officer

+44 (0)1925 742 000

Chris Sedwell - Chief Financial Officer

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash / James Thompson - Corporate Finance

Richard Chambers - ECM

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

byotrol@flagstaffcomms.com

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control company, operating globally in the animal health, human health, facilities management, and consumer sectors.

 

Byotrol develops unique antimicrobial technologies for use on surfaces, skin and instruments, which it then commercialises through market-leading distribution partners in each sector.

 

Byotrol's antimicrobial technologies can be licensed for use in leading brands, to significantly improve their product claims, while reassuring consumers and end-users of their efficacy and quality.

 

Founded in 2005, the Company develops technologies and products with the aim of providing easier, safer and cleaner lives for everyone. 

 

 

 

 

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Chris Sedwell

2. 

Reason for the notification

a)

Position/status:

Chief Financial Officer

b)

Initial notification/Amendment:

Initial Notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Byotrol plc

b)

LEI:

213800AJMTSTIPA59A34

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 0.25 pence per share

GB00B0999995

b)

Nature of the transaction:

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s):

Price(s)

Volume(s)

2.640p

2.629p

2.624p

 

37,519

37,676

113,241

d)

Aggregated information:

·Aggregated volume:

·Price:

 

 

188,436 Ordinary Shares

£4,952.44

 

e)

Date of the transaction:

7 September 2022

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDZGGLVNGGZZM
Date   Source Headline
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.